Skip to content
HowShorted

LIGAND PHARMACEUTICALS INC short interest in 2018

In 2018, LIGAND PHARMACEUTICALS INC's disclosed short interest ran from 16.97% of shares outstanding on 12 Jan 2018 to 34.74% on 31 Dec 2018, a change of +17.77 percentage points. The year's high was 34.74% on 31 Dec 2018 and its low 16.80% on 29 Mar 2018, averaging 20.81% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.12 days on 13 Jul 2018. Full history: LIGAND PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for LIGAND PHARMACEUTICALS INC in 2018

2018 in figures

Start of year
16.97% (12 Jan 2018)
End of year
34.74% (31 Dec 2018)
Change
+17.77 pp
High
34.74% (31 Dec 2018)
Low
16.80% (29 Mar 2018)
Average
20.81%
Highest days to cover
19.12 (13 Jul 2018)
SEC filings marked
8

Every report in 2018

LIGAND PHARMACEUTICALS INC short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201816.97%16.71
31 Jan 201817.70%9.44
15 Feb 201817.33%13.23
28 Feb 201817.04%15.97results (8-K)
15 Mar 201817.08%9.1910-K filed
29 Mar 201816.80%8.96
13 Apr 201817.24%13.63
30 Apr 201817.92%16.40
15 May 201818.11%10.83results (8-K), 10-Q filed
31 May 201820.18%9.39
15 Jun 201821.02%14.14
29 Jun 201820.90%11.08
13 Jul 201821.19%19.12
31 Jul 201819.17%14.88
15 Aug 201817.78%9.25results (8-K), 10-Q filed
31 Aug 201817.31%10.52
14 Sep 201818.74%11.10
28 Sep 201817.84%8.85
15 Oct 201819.37%5.62
31 Oct 201826.45%7.37
15 Nov 201828.84%5.3210-Q filed, results (8-K)
30 Nov 201829.11%13.57
14 Dec 201830.65%12.79
31 Dec 201834.74%12.37

See also: LIGAND PHARMACEUTICALS INC's full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.